Viewing Study NCT00506701



Ignite Creation Date: 2024-05-05 @ 6:34 PM
Last Modification Date: 2024-10-26 @ 9:34 AM
Study NCT ID: NCT00506701
Status: WITHDRAWN
Last Update Posted: 2015-03-18
First Post: 2007-07-23

Brief Title: Effect of Tadalafil in Chronic Obstructive Lung Disease Patients Suffering From Secondary Pulmonary Hypertension
Sponsor: Herlev Hospital
Organization: Herlev Hospital

Study Overview

Official Title: Pilot Study to Investigate the Effect of Tadalafil on Secondary Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease
Status: WITHDRAWN
Status Verified Date: 2007-07
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: due to lack of finance
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Tadalafil may lower the pulmonary artery pressure in patients with Chronic Obstructive Lung Disease and secondary pulmonary hypertension and thereby improve patients quality of life
Detailed Description: Twenty outpatients with Chronic Obstructive Lung Disease COPD and secondary pulmonary hypertension are treated in a cross-over design with Tadalafil or placebo for 4 weeks Primary effect parameter is 6 min walking test

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None